International application No. PCT/CA2004/001918

A. CLASSIFICATION OF SUBJECT MATTER

PC7: C07K-7/06 A61K-31/436 C07K-1/00 C07K-5/04 A61K-38/04 A61L-31/08 A61L-31/16 A61P-37/00 C07D-498/14

According to International Patent Classification (IPC) or to both national classification and IPC

#### **B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols) IPC7: C07K A61K A61L A61P C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used) Delphion, Pubmed, Caplus, Registry (Structure search)

Keywords: rapamycin, derivative, conjugate, amino acid, peptide, carbamate, cell cycle.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

/ Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No(s).
X	US 5,411,967 A (AMERICAN HOME PRODUCTS CORPORATION, Madison, N.J.), 2 May, 1995. Whole Document.	1 to 6 and 14 to 18
Á	EP 0509795 A2 (AMERICAN HOME PRODUCTS CORPORATION, New York, N.Y.) 21 October, 1992. Whole Document.	1 to 3 and 14 to 18
A	US 5,385,910 A (AMERICAN HOME PRODUCTS CORPORATION, Madison, N.J.), 31 January, 1995. Whole Document.	1 to 3 and 14 to 18

#### [X] Further documents are listed in the continuation of Box C. [X] See patent family annex. Special categories of cited documents: document defining the general state of the art which is not considered "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot earlier application or patent but published on or after the international filing date "E" filing date document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other be considered novel or cannot be considered to involve an "L" the considered investor and the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document "O" is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family ۲P document published prior to the international filing date but later than the priority date claimed "&" Date of the actual completion of the international search Date of mailing of the international search report '.07 February 2005 (07-02-2005) 14 March 2005 (14-03-2005) Name and mailing address of the ISA/CA Authorized officer

} .

Nathalie Chartrand (819) 994-2341

Name and maning address of the ISA/CA
Canadian Intellectual Property Office
Place du Portage I, C114 - 1st Floor, Box PCT
50 Victoria Street
Gatineau, Quebec K1A 0C9

Facsimile No: 001(819)953-2476

Conunaac	on). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No(s).
	WO 96/41807 A1 (SANDOZ-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]), 27 December, 1996. Whole Document.	1 to 9 and 14 to 18
	WO 03/057218 A1 (NOVARTIS AG [CH/CH]), 17 July, 2003. Whole Document.	7 to 13
	US 6,585,764 B2 (CORDIS CORPORATION, Miami Lakes, FL (US)), 1 July, 2003. Whole Document.	10 to 13
		· · ·

			ational application No. CA2004/001918
Box N	Vo. Ц		ontinuation of item 2 of the first sheet)
This	intern	national search report has not been established in respect of certain claims un	der Article 17(2)(a) for the following reasons:
7;	P [2	[X] Claim Nos.: 4 to 9, 15 and 16 because they relate to subject matter not required to be searched by this Auth-	ority, namely :
	A	Although claims 4 to 9, 15 and 16 are methods of treatment of the human/ani under Rule 39.1(iv) of the PCT, the search has been carried out based on the	mal body which this Authority is not obliged to search alleged effects of the compounds defined in claim 1.
8.	Ī.	[] Claim Nos.: because they relate to parts of the international application that do not comply no meaningful international search can be carried out, specifically:	with the prescribed requirements to such an extent that
9.		[] Claims Nos.: because they are dependant claims and are not drafted in accordance with the	second and third sentences of Rule 6.4(a).
Box l	Yo. II	III Observations where unity of invention is lacking (Continuation	
		tional Searching Authority found multiple inventions in this international app	incation, as follows .
10.	[]	[] As all required additional search fees were timely paid by the applicant, to claims.	nis international search report covers all searchable
. 11.		[ ] As all searchable claims could be searched without effort justifying an adaptional fee.	ditional fee, this Authority did not invite payment of
12.	[]	As only some of the required additional search fees were timely paid by those claims for which fees were paid, specifically claim Nos.:	ne applicant, this international search report covers only
•			e was the
13.	[]	] No required additional search fees were timely paid by the applicant. Con to the invention first mentioned in the claims; it is covered by claim Nos.	sequently, this international search report is restricted:

The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

[]

Remark on Protest

International application No. PCT/CA2004/001918

The structure of rapamycin seems to be erroneous in the application. The rapamycin ring system of the application comprises a surperfluous carbon (located between the conjugated double bonds and a carbonyl group) compared to the rapamycin ring system found in the art. Since the crux of the invention resides in the substituents located at the 42 position of rapamycin and not in the ring system, the ring system of rapamycin commonly disclosed in the art was used as the basis for the search.

Information on patent family members

•			;	
Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date	
US5411967	02-05-1995	AU679931 B2 AU4894293 A BR1100836 A3 BR9304211 A CA2108068 A1 CN1036591C C EP0593227 A1 EP1266900 A1 FI106463B B1 GB9317596D D0 HU70199 A2 IL107190 A JP6211870 A MX9306271 A1 NZ248909 A PH31253 A RU2126409 C1 SG47580 A1 US5302584 A US5411967 A US5434260 A US5484791 A US5484791 A US5486522 A US5486524 A US5486524 A US5486524 A US5486524 A US5486524 A US5486521 A US5486521 A US5486521 A US5486521 A US5580301 A US5500301 A US5500301 A US5530121 A US5530121 A US5559110 A US5559110 A US5559110 A US5559120 A US5559120 A US55597709 A ZA9307515 A	17-07-1997 28-04-1994 06-06-2000 07-06-1994 14-04-1994 13-12-1997 20-04-1994 18-12-2002 15-02-2001 06-10-1993 28-09-1995 30-09-1997 02-08-1994 29-04-1994 27-11-1995 18-06-1998 20-02-1999 17-04-1998 12-04-1994 02-05-1995 18-07-1996 02-01-1996 16-01-1996 16-01-1996 23-01-1996	
EP0509795	21-10-1992	AU642592 B2 AU1488092 A CA2065790 A1 CA2065791 A1 GZ9201173 A3 EP0509795 A2 FI921595 A HU9201254D D0 IE921249 A1 JP5112573 A MX9201710 A1 NO9201449 A NZ242367 A SK117392 A3 US5118678 A US5194447 A US5262424 A ZA9202738 A	21-10-1993 22-10-1992 18-10-1992 19-08-1993 21-10-1992 18-10-1992 28-07-1992 21-10-1992 07-05-1993 01-01-1993 19-10-1992 26-07-1994 12-04-1995 02-06-1992 16-03-1993 16-11-1993	

Information on patent family members

US5385910	31-01-1995	US5385910 A	31-01-1995	
F:				
WO9641807		AT228135T T AU712193 B2	15-12-2002 28-10-1999	
		AU6300696 A	09-01-1997	
		BR9609260 A	18-05-1999	
		CA2219659 A1	27-12-1996	
		CN1124276C C CZ292233 B6	15-10-2003 13-08-2003	
		DE69624921D D1	02-01-2003	
		DE69624921T T2	11-09-2003	
		DK833828T T3	17-03-2003	
		EP0833828'A1 ES2187660T T3	08-04-1998 16-06-2003	
		Fi113051B B1	27-02-2004	
		GB9511704D D0	02-08-1995	
		GB9513754D D0	96-09-1995	
		HK1014949 A1	09-07-2004 01-03-4000	
		HU9802200 A2 IL122212 A	01-02-1999 26-08-2001	
		JP3226545B2 B2	05-11-2001	
		NO975432 A	26-11-1997	
		NZ311647 A	29-11-1999 31-12-2002	
		PL184731B B1 PT833828T T	28-02-2003	Section of the sectio
		RU2158267 C2	27-10-2000	
		SI833828T T1	30-06-2003	
		SK168297 A3	06-05-1998	
		TR9701567T T1 TW410226 B	· 21-04-1998 01-11-2000	er rem
		US5985890 A	16-11-1999	
		US6200985 B1	13-03-2001	
		WO9641807 A1	27-12-1996	
		ZA9604870 A	08-12-1997	
WÖ03057218	17-07-2003	AU2003205586 A1	24-07-2003	
1		BR0306858 A	03-11-2004	
		CA2472198 A1	17-07-2003	
		EP1465624 A1 US2003170287 A1	13-10-2004 11-09-2003	· .
•		US2005020614 A1	27-01-2005	
		WO03057218 A1	17-07-2003	
		: :		
US6585764		AT263520T T	15-04-2004	
		AU1129902 A	08-04-2002	
		AU1132102 A AU5977401 A	08-04-2002 26-11-2001	
		AU6157901 A	26-11-2001	
		AU6158001 A	26-11-2001	•
		AU6158101 A	26-11-2001	
		AU6295701 A AU6311201 A	26-11-2001 26-11-2001	
		AU6311301 A	26-11-2001 26-11-2001	
		AU7730201 A	11-04-2002	
		AU9316101 À	08-04-2002	•
		AU9486901 A	08-04-2002	
		AU2003203791 A1 AU2003203891 A1	06-11-2003 · 20-11-2003	•
		AU2003203031 A1	11-12-2003	
		CA2269310 A1	16-10-1999	
		CA2357881 A1	29-03-2002	
		CA2408606 A1	22-11-2001 22-11-2001	
		CA2408608 A1 CA2408719 A1	22-11-2001 22-11-2001	
		CA2408729 A1	22-11-2001	
		GA2408752 A1	22-11-2001	
		CA2408754 A1	22-11-2001	
		CA2408838 A1	22-11-2001	
		•	•	

Information on patent family members

<del></del>	,
040404000 44	04-04-2002
CA2424029 A1	
CA2424038 A1	04-04-2002
CA2424049 A1	04-04-2002
CA2425753 A1	04-04-2002
CA2426332 Å1	22-10-2003
CA2426974 A1	30-10-2003
CA2429059 A1	20-11-2003
CA2436342 A1	30-01-2004
CA2442327 A1	10-10-2002
CA2445654 A1	21-04-2004
CA2445655 A1	21-04-2004
CA2450962 A1	03-01-2003
CN1477980T T	25-02-2004
DE69916157D D1	13-05-2004
EP0950386 A2	20-10-1999
EP1192957 A2	03-04-2002
EP1280512 A2	05-02-2003
EP1280568 A1	05-02-2003
EP1280569 A1	05-02-2003
EP1280570 A2	05-02-2003
EP1280571 A1	05-02-2003
EP1280572 A1	05-02-2003
EP1289576 A1	12-03-2003
EP1322235 A1	12-03-2003 02-07-2003
EP1322342 A1	02-07-2003
EP1322351 A1	02-07-2003
	20-08-2003
EP1356789 A1	29-10-2003
EP1360967 A1	12-11-2003
EP1362602 A1	19-11-2003
EP1364628 A1	26-11-2003
EP1372752 A1	02-01-2004
EP1386624 A1	04-02-2004
EP1406682 A1	14-04-2004
EP1407726 A1	14-04-2004
EP1413256 A1	28-04-2004
EP1421909 A1	26-05-2004
ES2218953T T3	16-11-2004
JP2002238994 A	27-08-2002
JP2003334256 A	25-11-2003
JP2003533493T T	11-11-2003
JP2003533494T T	11-11-2003
JP2003533495T T	11-11-2003
JP2003533496T T	11-11-2003
JP2004000559 A	08-01-2004
JP2004000586 A	08-01-2004
JP2004130101 A	30-04-2004
JP2004141660 A	20-05-2004
JP2004154541 A	03-06-2004
JP2004275733 A	07-10-2004
JP2004501102T T	15-01-2004
JP2004504078T T	12-02-2004
JP2004516235T T	03-06-2004
JP2004518458T T	24-06-2004
JP2004521668T T	22-07-2004
JP2004524868T T	19-08-2004
JP2004524916T T	19-08-2004
JP2004531331T T	14-10-2004
DT050295T T	
PT950386T T	31-08-2004
US6273913 B1	14-08-2001
US6585764 B2	01-07-2003
US6746773 B2	08-06-2004
US6776796 B2	17-08-2004
US6788202 B2	07-09-2004
US6808536 B2	26-10-2004
US2001029351 A1	11-10-2001
US2002005208 A1	17-01-2002
US2002007213 A1	17-01-2002
US2002007214 A1	17-01-2002
US2002007215 A1	17-01-2002
US2002051730 A1	02-05-2002
US2002111590 A1	15-08-2002
US2002133183 A1	19-09-2002
US2002143386 A1	03-10-2002
US2002165608 A1	07-11-2002
US2002193867 A1	19-12-2002
	10-12-2002

Information on patent family members

US2003060877 A1 US2003065345 A1 US2003065346 A1 US2003065377 A1 US20032044168 A1 US2003216699 A1 US2004102758 A1 US2004197372 A1 US2004243097 A1 US2004260268 A1 US2005002986 A1 US20050033261 A1 WO0187263 A2	27-03-2003 03-04-2003 03-04-2003 30-10-2003 20-11-2003 27-05-2004 07-10-2004 02-12-2004 23-12-2004 06-01-2005 10-02-2005 22-11-2001
US2005002986 A1	06-01-2005
US2005004663 A1	06-01-2005
WO0187342'A2	22-11-2001
WO0187372 A1 WO0187373 A1	22-11-2001 22-11-2001
WO0187374 A1 WO0187375 A1	22-11-2001 22-11-2001